| Asthma |
1 |
1 |
| Mechanical Ventilation |
0 |
0.92 |
| Otolaryngology |
0 |
0.7 |
| Lung |
0 |
0.5 |
| Lung Fibrosis |
0 |
0.41 |
| Interstitial Lung Disease |
0 |
0.39 |
| Extubation |
0 |
0.33 |
| Thorax |
0 |
0.33 |
| Airway |
0 |
0.32 |
| Allergy |
0 |
0.28 |
| Clinical Guidelines |
0 |
0.28 |
| Intubation |
0 |
0.28 |
| Cough |
0 |
0.22 |
| Neuromuscular Diseases |
0 |
0.22 |
| Chronic Obstructive Pulmonary Disease |
0 |
0.19 |
| Pleural Effusion |
0 |
0.17 |
| Biologic Therapy |
0 |
0.14 |
| Biomarker |
0 |
0.11 |
| Food and Drug Administration (FDA) |
0 |
0.11 |
| Pulmonary Function Test |
0 |
0.11 |
| Remission |
0 |
0.11 |
| Sleep |
0 |
0.11 |
| Heart Failure (HF) |
0 |
0.09 |
| Obesity |
0 |
0.08 |
| Recombinant Human Monoclonal Antibody |
0 |
0.08 |
| Hypertension |
0 |
0.07 |
| Idiopathic Pulmonary Fibrosis |
0 |
0.07 |
| Muscular Dystrophy |
0 |
0.07 |
| Pneumonia |
0 |
0.07 |
| Adherence |
0 |
0.06 |
| Adverse Effects |
0 |
0.06 |
| Atelectasis |
0 |
0.06 |
| Clinical Research |
0 |
0.06 |
| Drug Development |
0 |
0.06 |
| Dyspnea |
0 |
0.06 |
| Dystrophinopathies |
0 |
0.06 |
| Grant |
0 |
0.06 |
| Health Care Cost |
0 |
0.06 |
| Heart |
0 |
0.06 |
| Hospital |
0 |
0.06 |
| Impairment |
0 |
0.06 |
| Liver |
0 |
0.06 |
| Monoclonal Antibody |
0 |
0.06 |
| Nitric Oxide |
0 |
0.06 |
| Noninvasive Ventilation |
0 |
0.06 |
| Pandemic |
0 |
0.06 |
| Patient Safety |
0 |
0.06 |
| Pulmonary Arterial Hypertension |
0 |
0.06 |
| Pulmonary Hypertension |
0 |
0.06 |
| Respiratory Failure |
0 |
0.06 |
| Targeted Cancer Therapy |
0 |
0.06 |
| Thoracentesis |
0 |
0.06 |
| Tissue |
0 |
0.06 |
| Transplantation |
0 |
0.06 |
| Ventilator |
0 |
0.06 |
| Weakness |
0 |
0.06 |
| COVID-19 |
0 |
0.04 |
| Multiple Sclerosis |
0 |
0.04 |
| Renal Failure |
0 |
0.04 |